Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Fleming

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Biomacromolecules|March 24, 2016
A Nanoparticle Platform To Evaluate Bioconjugation and Receptor-Mediated Cell Uptake Using Cross-Linked Polyion Complex Micelles Bearing Antibody FragmentsStelios Florinas, Marc Liu, Ryan Fleming, et al.
Mabs|March 6, 2019
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimerJason B White, Ryan Fleming, Luke Masterson, et al.
Cancer Research|November 18, 2008
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivoDowdy Jackson, John Gooya, Shenlan Mao, et al.
Cancer Research|March 12, 2017
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple ImmunotherapiesJonathan Rios-Doria, Jay Harper, Raymond Rothstein, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 22, 2016
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokineticsPamela Thompson, Ryan Fleming, Binyam Bezabeh, et al.
Science Translational Medicine|November 14, 2014
A multifunctional bispecific antibody protects against Pseudomonas aeruginosaAntonio DiGiandomenico, Ashley E Keller, Cuihua Gao, et al.
Molecular Cancer Therapeutics|May 15, 2020
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive CellsRuoyan Chen, Saravanan Rajan, Michael G Overstreet, et al.
Leukemia|October 14, 2018
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cellsKrista Kinneer, Matt Flynn, Suneetha B Thomas, et al.
Molecular Cancer Therapeutics|March 3, 2021
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATRShenlan Mao, Raghothama Chaerkady, Wen Yu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 24, 2025
Multiomic Immune Profiling of Pediatric Transplant Recipients Identifies Cell States Associated with Vaccine ResponseJohannes Wedel, Ying Tang, Bayan Alsairafi, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Biomacromolecules|March 24, 2016
A Nanoparticle Platform To Evaluate Bioconjugation and Receptor-Mediated Cell Uptake Using Cross-Linked Polyion Complex Micelles Bearing Antibody FragmentsStelios Florinas, Marc Liu, Ryan Fleming, et al.
Mabs|March 6, 2019
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimerJason B White, Ryan Fleming, Luke Masterson, et al.
Cancer Research|November 18, 2008
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivoDowdy Jackson, John Gooya, Shenlan Mao, et al.
Cancer Research|March 12, 2017
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple ImmunotherapiesJonathan Rios-Doria, Jay Harper, Raymond Rothstein, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 22, 2016
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokineticsPamela Thompson, Ryan Fleming, Binyam Bezabeh, et al.
Science Translational Medicine|November 14, 2014
A multifunctional bispecific antibody protects against Pseudomonas aeruginosaAntonio DiGiandomenico, Ashley E Keller, Cuihua Gao, et al.
Molecular Cancer Therapeutics|May 15, 2020
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive CellsRuoyan Chen, Saravanan Rajan, Michael G Overstreet, et al.
Leukemia|October 14, 2018
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cellsKrista Kinneer, Matt Flynn, Suneetha B Thomas, et al.
Molecular Cancer Therapeutics|March 3, 2021
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATRShenlan Mao, Raghothama Chaerkady, Wen Yu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 24, 2025
Multiomic Immune Profiling of Pediatric Transplant Recipients Identifies Cell States Associated with Vaccine ResponseJohannes Wedel, Ying Tang, Bayan Alsairafi, et al.
Pageof 4